I am not for this world

I am a scientist who suffers from anxiety and depression. Here I gather inspiration and help. You are not alone.

[iamnotforthisworld]

Psychedelic drugs, such as lysergic acid diethylamide (LSD), mescaline, and psilocybin, exert profound effects on brain and behavior. After decades of difficulties in studying these compounds, psychedelics are again being tested as potential treatments for intractable biomedical disorders. Preclinical research of psychedelics complements human neuroimaging studies and pilot clinical trials, suggesting these compounds as promising treatments for addiction, depression, anxiety, and other conditions. However, many questions regarding the mechanisms of action, safety, and efficacy of psychedelics remain. Here, we summarize recent preclinical and clinical data in this field, discuss their pharmacological mechanisms of action, and outline critical areas for future studies of psychedelic drugs, with the goal of maximizing the potential benefits of translational psychedelic biomedicine to patients.

[iamnotforthisworld]

Health policies and programs promoting mental health or preventing mental illness in the general public are under-recognized facets of primary prevention. Increasing awareness and adoption of such strategies could reduce the burden of mental illness in individuals, families, communities, and society as whole. We conducted a scoping review of reviews of interventions to promote mental health or prevent mental illness. We searched PubMed, PsycINFO, Scopus, Cochrane CENTRAL, CINAHL and ERIC from 2004 to 2014. Reviews were included if the authors indicated a systematic approach in their literature searches, and if they comprised interventions in Westernized countries targeting the general population. We identified 39 reviews that met the inclusion criteria. Mental health intervention approaches and outcomes varied across age groups and settings, and included functional, social, and cognitive measures. Most interventions aimed to prevent a specific mental illness or symptoms (depression, anxiety, burnout, or stress). Cognitive-behavioral therapy and educational components were common. School-based programs focused on outcomes involving social and academic development. Interventions for families, especially for young or disadvantaged parents, taught parenting skills to help improve the well-being of children and their care-givers. In the workplace, the focus was on managing stress, while programs for the elderly emphasized quality of life determinants. This review summarizes a wide variety of interventions to promote mental health or prevent mental illness, but the literature is primarily focused on the individual or family unit. More information is required about interventions at the community and societal levels.

[iamnotforthisworld]

“Safety first,” we say these words almost every day, but we all take this for granted for what Maslow proposed in his famous theory ofHierarchy of Needs: safety needs come second to physiological needs. Here we propose that safety needs come before physiological needs. Safety needs are personal security, financial security, and health and well-being, which are more fundamental than physiological needs. Safety worrying is the major reason for mental disorders, such as anxiety, phobia, depression, and PTSD. The neural basis for safety is amygdala, LC/NE system, and corticotrophin-releasing hormone system, which can be regarded as a “safety circuitry,” whose major behavior function is “fight or flight” and “fear and anger” emotions. This is similar to the Appraisal theory for emotions: fear is due to the primary appraisal, which is related to safety of individual, while anger is due to secondary appraisal, which is related to coping with the unsafe situations. If coping is good, the individual will be happy; if coping failed, the individual will be sad or depressed

[iamnotforthisworld]

Med Clin North Am. 2017 Sep;101(5):847-864. doi: 10.1016/j.mcna.2017.04.004. Epub 2017 Jun 20. Review

[iamnotforthisworld]

How does MoodNetwork work? First, we bring together people with mood disorders, clinicians, and researchers. Second, we gather a lot of data about depression and bipolar disorder. With this much information, our study can lead to greater understanding and better treatments.

[iamnotforthisworld]

It’s perfectly normal for someone to feel anxious or depressed after receiving a diagnosis of a serious illness. But what if the reverse occurs and symptoms of anxiety or depression masquerade as an as-yet undiagnosed physical disorder? Or what if someone’s physical symptoms stem from a psychological problem? How long might it take before the true cause of the symptoms is uncovered and proper treatment begun?

[iamnotforthisworld]

The Minnesota Multiphasic Personality Inventory (MMPI) is a standardized psychometric test of adult personality and psychopathology. Psychologists and other mental health professionals use various versions of the MMPI to help develop treatment plans; assist with differential diagnosis; help answer legal questions (forensic psychology); screen job candidates during the personnel selection process; or as part of a therapeutic assessment procedure. (Source: Wikipedia)

[iamnotforthisworld]

[iamnotforthisworld]

Biopharmaceutical Research Companies are Developing More Than 130 Medicines for Mental Illnesses Mental illnesses exact a heavy human and economic toll in the United States. The National Institute of Mental Health (NIMH) estimates that one in five American adults and children experience a mental illness in any given year amounting to more than $317 billion annually in the U.S. in lost wages, health care expenditures and disability benefits. Over the past half century, biopharmaceutical research has helped transform this misunderstood set of diseases into often highly treatable conditions. However, additional therapeutic options are needed for patients not helped by existing treatments and to address unmet medical needs. Biopharmaceutical companies are working closely with patients, regulators, academia and clinicians on the cutting-edge medicine and research needed to bring new medicines to patients. Medicines for Mental Illnesses in the Pipeline Researchers are seeking to leverage a growing understanding of the innerworkings of mental illnesses. Current studies are examining how existing treatments work and are identifying biomarkers that can be used to both improve diagnoses and also to assess a patients’ response to therapies. Biomarkers are also increasingly being used to find new therapeutic targets through identification of the pathologies or mechanisms contributing to mental illness. Today, 135 medicines2 are currently in development by biopharmaceutical research companies to help the more than 40 million Americans su ering from some form of mental illness — from anxiety to depression and from schizophrenia to addictive disorders, such as dependence and addiction to alcohol or drugs. All of the medicines in development are either in clinical trials or awaiting review by the U.S. Food and Drug Administration. These potential treatment advances include: • 40 for schizophrenia, which a ects approxi- mately one percent of U.S. adults.1 • 29 for depression, including major depressive disorder which a ects 15.7 million adults and 2.8 million adolescents ages 12 to 17 in the United States.1 • 28 for substance abuse and addiction disorders. Nearly 25 million Americans ages 12 and older have reported using an illicit drug in the past month.3 • 14 for anxiety disorders which a ect 18 percent of U.S. adults and 25 percent of adolescents ages 13 to 18.1 • 10 for pediatric patients with mental illnesses, which a ect one in five children ages 13 to 18.2 Challenges in Research for Mental Illnesses Development of new and e ective treatments for patients with mental illnesses is very challenging. There is a limited understanding of how current treatments work in the brain and a need for robust and qualified biomarkers to help clinicians’ diagnose accurately, measure disease progression and assess treatment response. Conducting pediatric research is especially challenging with special technical, scientific, ethical and medical considerations introducing unique obstacles and smaller patient populations. America’s biopharmaceutical companies are working to advance innovative approaches in clinical trial methodology in order to advance treatments for patients with mental illnesses, especially for pediatric patients where there is such urgent need. Source: Pharma.org

[iamnotforthisworld]

Biopharmaceutical research companies are currently developing 119 medicines to help people who have some type of mental disorder, such as anxiety, depres- sion, schizophrenia, or substance use disorders. Those medicines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA), with more than 75 percent of the medicines in the earliest phases of research and development—a time when potential treatments often face difficult hurdles and setbacks.

[regardintemporel]

Keiji Iwai - Aspen Trees, 1995

[iamnotforthisworld]

Neurons

[iamnotforthisworld]

Liminal 1. relating to a transitional or initial stage of a process. 2. occupying a position at, or on both sides of, a boundary or threshold.

[iamnotforthisworld]

Mind

[iamnotforthisworld]

OBJECTIVES: Depression is one of the most common psychiatric disorders, and the fourth leading cause of long-term disability throughout the world. Despite the availability of different classes of antidepressant drugs, most of them are not completely effective and above all are associated with many serious adverse effects. Recently, accumulating evidence suggests that dietary supplements rich in important phytochemicals possess beneficial therapeutic roles in depression. METHODS: In this review, we will first consider what is known about the pathogenesis of depression and discuss the need for more safe and efficacious treatment. We will then review the potential clinical relevance of natural plant-derived products based on data derived from pre-clinical animal studies, randomized controlled studies and placebo-controlled trials published on this topic within the last decade. RESULTS: Among the natural compounds that show antidepressive-like activity, green tea catechins have been shown to decrease depressive symptoms in experimental animals, possibly in part through the inhibition of monoamine oxidase (MAO). Anthocyanins and their aglycons, responsible for the typical color of berries, inhibit MAO isoforms A or B with IC50 values corresponding to the micromolar range. Other studies suggest that cocoa extracts, whose main components are procyanidins, attenuate depressive symptoms in rats. Resveratrol, one of the most important natural stilbenoid, inhibits noradrenaline and serotonin reuptake in rats, and significantly decreases anxiety/depressive behaviours while increasing hippocampal serotonin and noradrenaline levels. Trans-resveratrol possesses MAO-A inhibitory effects in different brain areas, particularly in the frontal cortex and hippocampus, as already reported for tea catechins. Although these effects have been documented in rodent models, further randomized controlled trials in this area are warranted. However, so far, there is only correlative evidence between certain nutrients, such as omega-3 polyunsaturated fatty acids and B vitamins, and depression in human population studies. DISCUSSION: Growing evidence suggests that consumption of these compounds may represent an alternative strategy to delay the onset and progression of depression, and depressive-like symptoms. However, further randomized and placebo-controlled trials are necessary to confirm the potential of these compounds as a possible remedy for this debilitating disorder.

[guitarplayermrs]

[iamnotforthisworld]

Me neither

[iamnotforthisworld]

[iamnotforthisworld]

Our mission is to create an environment of trust and support through open dialogue, education, empowerment, and positive change